Mauna Kea Technologies Announces it has Signed its 15th Hospital in Europe for Irritable Bowel Syndrome (IBS) Food Allergy Application
Confirming the Role and added value of Cellvizio for the Identification and Management of IBS Patients with Atypical Food Allergies Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY)